NeuroOne Medical Technologies Files 8-K

Ticker: NMTC · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1500198

Neuroone Medical Technologies CORP 8-K Filing Summary
FieldDetail
CompanyNeuroone Medical Technologies CORP (NMTC)
Form Type8-K
Filed DateMar 15, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, regulatory-filing

TL;DR

NeuroOne Medical files 8-K covering votes, Reg FD, and financials.

AI Summary

NeuroOne Medical Technologies Corp. filed an 8-K on March 14, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing also details the company's principal executive offices located at 7599 Anagram Dr., Eden Prairie, MN 55344, and its phone number (952) 426-1383.

Why It Matters

This 8-K filing provides updates on corporate governance and regulatory matters for NeuroOne Medical Technologies, which could impact investor confidence and future strategic decisions.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What is the primary business of NeuroOne Medical Technologies Corp.?

NeuroOne Medical Technologies Corp. is in the business of Surgical & Medical Instruments & Apparatus, as indicated by its SIC code 3841.

When was the company incorporated?

The company was incorporated in Delaware.

What is the IRS Employer Identification Number for NeuroOne Medical Technologies Corp.?

The IRS Employer Identification Number is 27-0863354.

What is the former name of the company?

The former name of the company was Original Source Entertainment, Inc., with a date of name change on August 30, 2010.

Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-03-15 16:30:57

Key Financial Figures

Filing Documents

07. Submission of Matters to a Vote of Security

Item 5.07. Submission of Matters to a Vote of Security Holders. At the annual meeting (the "Annual Meeting") of stockholders of NeuroOne Medical Technologies Corporation (the "Company") on March 14, 2024, stockholders (i) elected one Class I director to the Company's Board of Directors, to serve a three-year term until the 2027 annual meeting of stockholders, (ii) ratified the appointment of Baker Tilly U.S., LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2024, (iii) approved the Company's named executive officers' compensation in an advisory vote, and (iv) approved, on an advisory basis, to conduct an advisory vote on the frequency of future advisory votes on executive compensation every three years. Proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 29, 2024. A total of 15,782,424 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 60.89% of the shares of common stock outstanding as of the record date for the Annual Meeting. The results of the voting are shown below: Proposal 1—Election of Directors Class I Nominee Votes For Votes Withheld Broker Non-Votes Paul Buckman 5,804,908 1,363,109 8,614,407 Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 15,736,069 36,991 9,364 Proposal 3—Approval of the Company's Named Executive Officers' Compensation in an Advisory Vote Votes For Votes Against Votes Abstain 6,586,582 330,506 250,929 Proposal 4—Advisory Approval of the Frequency of an Advisory Vote on Named Executive Officers Compensation One Year Two Years Three Years Votes Abstain 3,060,695 144,245 3,723,836 239,241 For Proposal 4, "every three years" received the affirmative vote of the holders of a majority of

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On March 15, 2024, the Company posted an updated corporate presentation to its website at https://nmtc1.com/investors, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report. The information in this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company's submission of this Current Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. This Current Report and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated March 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: March 15, 2024 By: /s/ David Rosa David Rosa Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing